Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial
- PMID: 26821623
- DOI: 10.1016/j.jacc.2015.10.081
Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial
Abstract
Background: Whether cyclosporine A (CsA) has beneficial effects in reperfused myocardial infarction (MI) is debated.
Objectives: This study investigated whether CsA improved ST-segment resolution in a randomized, multicenter phase II study.
Methods: The authors randomly assigned 410 patients from 31 cardiac care units, age 63 ± 12 years, with large ST-segment elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 to 1 in the infarct-related artery, and committed to primary percutaneous coronary intervention, to 2.5 mg/kg intravenous CsA (n = 207) or control (n = 203) groups. The primary endpoint was incidence of ≥70% ST-segment resolution 60 min after TIMI flow grade 3. Secondary endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular (LV) remodeling, and clinical events at 6-month follow-up.
Results: Time from symptom onset to first antegrade flow was 180 ± 67 min; a median of 5 electrocardiography leads showed ST-segment deviation (quartile [Q]1 to Q3: 4 to 6); 49.8% of MIs were anterior. ST-segment resolution ≥70% was found in 52.0% of CsA patients and 49.0% of controls (p = 0.55). Median hs-cTnT on day 4 was 2,160 (Q1 to Q3: 1,087 to 3,274) ng/l in CsA and 2,068 (1,117 to 3,690) ng/l in controls (p = 0.85). The 2 groups did not differ in LV ejection fraction on day 4 and at 6 months. Infarct site did not influence CsA efficacy. There were no acute allergic reactions or nonsignificant excesses of 6-month mortality (5.7% CsA vs. 3.2% controls, p = 0.17) or cardiogenic shock (2.4% CsA vs. 1.5% controls, p = 0.33).
Conclusions: In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous CsA bolus just before primary percutaneous coronary intervention had no effect on ST-segment resolution or hs-cTnT, and did not improve clinical outcomes or LV remodeling up to 6 months. (CYCLosporinE A in Reperfused Acute Myocardial Infarction [CYCLE]; NCT01650662; EudraCT number 2011-002876-18).
Keywords: acute myocardial infarction; echocardiography; left ventricular function; troponins.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Cyclosporine A Prior to Primary PCI in STEMI Patients: The Coup de Grâce to Post-Conditioning?J Am Coll Cardiol. 2016 Feb 2;67(4):375-378. doi: 10.1016/j.jacc.2015.11.024. J Am Coll Cardiol. 2016. PMID: 26821624 No abstract available.
Similar articles
-
Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty.Circ Cardiovasc Interv. 2009 Oct;2(5):376-83. doi: 10.1161/CIRCINTERVENTIONS.109.852665. Epub 2009 Sep 15. Circ Cardiovasc Interv. 2009. PMID: 20031746 Clinical Trial.
-
The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study.J Am Coll Cardiol. 2008 Feb 5;51(5):552-9. doi: 10.1016/j.jacc.2007.09.051. J Am Coll Cardiol. 2008. PMID: 18237684
-
Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005. Am Heart J. 2012. PMID: 22305837 Clinical Trial.
-
[Non-invasive evaluation of coronary reperfusion. Analysis of the ST segment before and after thrombolysis in acute myocardial infarct].Minerva Cardioangiol. 1997 Sep;45(9):407-14. Minerva Cardioangiol. 1997. PMID: 9446061 Review. Italian.
-
Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.Am J Cardiovasc Drugs. 2004;4(3):159-67. doi: 10.2165/00129784-200404030-00003. Am J Cardiovasc Drugs. 2004. PMID: 15134468 Review.
Cited by
-
9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.Basic Res Cardiol. 2016 Jul;111(4):41. doi: 10.1007/s00395-016-0558-1. Epub 2016 May 10. Basic Res Cardiol. 2016. PMID: 27164905 Free PMC article. Review.
-
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery.Basic Res Cardiol. 2016 Nov;111(6):70. doi: 10.1007/s00395-016-0588-8. Epub 2016 Oct 20. Basic Res Cardiol. 2016. PMID: 27766474 Free PMC article. Review.
-
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8. Pharmacol Rev. 2023. PMID: 36753049 Free PMC article. Review.
-
Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control.Theranostics. 2021 May 3;11(14):6766-6785. doi: 10.7150/thno.60143. eCollection 2021. Theranostics. 2021. PMID: 34093852 Free PMC article. Review.
-
Nanoparticle-Mediated Delivery of Mitochondrial Division Inhibitor 1 to the Myocardium Protects the Heart From Ischemia-Reperfusion Injury Through Inhibition of Mitochondria Outer Membrane Permeabilization: A New Therapeutic Modality for Acute Myocardial Infarction.J Am Heart Assoc. 2016 Jul 22;5(7):e003872. doi: 10.1161/JAHA.116.003872. J Am Heart Assoc. 2016. PMID: 27451459 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous